United Therapeutics

United Therapeutics

UTHR· Manufacturing· Fiscal year ends in December

CEO pay in FY2025Stock +38.1% in FY2025

Martine A. Rothblatt is the CEO of United Therapeutics and was paid $18.0M in FY2025 (Dec), down 22%.

Pay$100 in the stock at the end of FY20 → $321
CEO pay is from each United Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Executives4

See all
  1. 1Martine A. RothblattFY2025
  2. 2Michael BenkowitzFY2025
  3. 3James EdgemondFY2025
  4. 4Paul MahonFY2025

Named executives and their total pay, from the Summary Compensation Table of the latest proxy.

Pay

See all

United Therapeutics paid its 4 named executives $46.3M in total in FY2025 (Dec). CEO Martine A. Rothblatt was paid $18.0M of that.

Name
Martine A. RothblattChairperson and Chief Executive Officer
Michael BenkowitzPresident and Chief Operating Officer
James EdgemondChief Financial Officer and Treasurer
Paul MahonExecutive Vice President and General Counsel

of each named executive, from the Summary Compensation Table of each proxy.

Peers25

See all

The FY2024 (Dec) proxy of United Therapeutics names 25 peer companies for pay. Among United Therapeutics and these peers, CEO pay was 4th highest of 12 and total shareholder return was the highest of 12.

4th highest of 12in United Therapeutics and its pay peers, FY2024 (Dec) by CEO pay:

$6.8M$24.4M

1st highest of 12in United Therapeutics and its pay peers, FY2024 (Dec) by total shareholder return:

$42$401

The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year.

Board3

See all
  • Christopher CauseyDirector · 21 yr on the boardIndependentAudit, Nominating and Governance (Chair)—Paid as an executive
  • Richard GiltnerDirector · 15 yr on the boardIndependentAudit (Chair), Nominating and Governance—Paid as an executive
  • Judy OlianDirector · 9 yr on the boardIndependentAudit—Paid as an executive

The board of the latest proxy (FY2024).

Activity

  1. Pay
    United Therapeutics General counsel pay fell 21% to $5.5M. The stock rose 38% in FY2025 (Dec).
    DEF 14A
  2. Pay
    United Therapeutics CEO pay fell 22% to $18.0M. The stock rose 38% in FY2025 (Dec).
    DEF 14A
  3. Pay
    United Therapeutics General counsel pay rose 35% to $7.0M. The stock rose 60% in FY2024 (Dec).
    DEF 14A
  4. Pay
    United Therapeutics COO pay rose 42% to $13.9M. The stock rose 60% in FY2024 (Dec).
    DEF 14A
  5. Pay
    United Therapeutics CEO pay rose 36% to $23.0M. The stock rose 60% in FY2024 (Dec).
    DEF 14A
  6. Pay
    United Therapeutics CFO pay rose 51% to $9.2M. The stock rose 60% in FY2024 (Dec).
    DEF 14A
  7. Pay
    United Therapeutics General counsel pay rose 123% to $5.2M. The stock fell 21% in FY2023 (Dec).
    DEF 14A
  8. Pay
    United Therapeutics General counsel pay rose 39% to $2.3M. The stock rose 29% in FY2022 (Dec).
    DEF 14A
  9. Pay
    United Therapeutics COO pay rose 247% to $9.8M. The stock fell 21% in FY2023 (Dec).
    DEF 14A
  10. Pay
    United Therapeutics COO pay rose 22% to $2.8M. The stock rose 29% in FY2022 (Dec).
    DEF 14A
  11. Pay
    United Therapeutics CEO pay rose 219% to $17.0M. The stock fell 21% in FY2023 (Dec).
    DEF 14A
  12. Pay
    United Therapeutics CEO pay rose 52% to $5.3M. The stock rose 29% in FY2022 (Dec).
    DEF 14A
  13. Pay
    United Therapeutics CFO pay rose 202% to $6.1M. The stock fell 21% in FY2023 (Dec).
    DEF 14A

Filings6

See all
Proxy statementDEF 14AApr 29, 2026FY2025
Annual report10-KFeb 25, 2026FY2025
Proxy statementDEF 14AApr 29, 2025FY2024
Annual report10-KFeb 26, 2025FY2024
Proxy statementDEF 14AApr 29, 2024FY2023
Annual report10-KFeb 21, 2024FY2023
For the press:Download CSVDownload PNGHow to use our data